Cannabidiol Market Size, Share and Growth Forecast 2026-2034

Market Overview:

According to IMARC Group's latest research publication, "Cannabidiol Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The global cannabidiol market size was valued at USD 8.1 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 27.6 Billion by 2034, exhibiting a CAGR of 14.25% during 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI is Reshaping the Future of the Cannabidiol Market

• AI-powered extraction optimization is helping CBD producers improve purity yields, with machine learning models identifying optimal CO2 and ethanol extraction parameters to deliver isolates reaching up to 99% cannabidiol purity.
• Predictive analytics tools are being applied across hemp cultivation, enabling farmers to monitor crop health in real time and reduce post-harvest cannabinoid loss, improving raw material efficiency across the supply chain.
• AI-driven personalization platforms are being used by CBD wellness brands to recommend product formats, dosages, and cannabinoid blends based on individual health profiles, supporting the shift toward targeted therapeutic applications.
• Natural language processing tools are supporting regulatory compliance teams in tracking fast-changing global cannabis laws, helping companies operating across North America, Europe, and Asia Pacific stay ahead of shifting CBD approval frameworks.
• In April 2026, Charlotte's Web, a leading U.S. CBD producer, was named an inaugural partner for the CMS Medicare CBD pilot program, which uses data-driven eligibility and prescribing models to bring physician-authorized CBD access into the healthcare system for seniors for the first time.

Download a sample PDF of this report: https://www.imarcgroup.com/cannabidiol-market/requestsample

Key Trends in the Cannabidiol Market

• Growing Legislative Changes and Legalization: Regulatory shifts across major economies are creating structured, accessible frameworks for CBD production and distribution. In February 2024, Germany decriminalized marijuana, permitting adults over 18 to possess up to 25 grams and grow up to three plants at home, while cannabis clubs were approved with a monthly member allowance of 50 grams. The 2018 U.S. Farm Bill legalized hemp-derived CBD, establishing a foundation that continues to support market expansion. These legal milestones have reduced entry barriers, increased consumer confidence, and enabled a broader range of CBD-infused product categories to enter retail and pharmaceutical channels.
  
  
• Increasing Awareness of CBD's Therapeutic Properties: Consumer recognition of CBD's health benefits is growing steadily, backed by clinical research and regulatory approvals. The U.S. FDA authorized Epidiolex, a hemp-derived cannabidiol medication for rare seizure disorders, establishing a precedent for CBD's acceptance within mainstream medicine. According to a Pew Research Center survey, approximately 90% of Americans support some form of marijuana legalization, with 88% favoring medical use. The American Psychiatric Association reported in 2024 that 43% of American adults aged 18 and above feel more anxious than they did the prior year, reinforcing demand for CBD-based anxiety and sleep management products.
  
  
• Rapid Product Innovation Across Categories: Companies are actively diversifying their CBD product portfolios beyond oils and capsules into edibles, topicals, beverages, cosmetics, and veterinary care items. In July 2026, cbdMD's Oasis brand partnered with Mexcor to enter the South Carolina market, expanding distribution of hemp-derived CBD products across new U.S. states. Additionally, cbdMD completed a self-affirmed Generally Recognized as Safe determination, supporting the safe consumption of up to 200 mg per day of cannabidiol, strengthening its position in the food-grade and supplement segments.
  
  
• Expansion of Pet Wellness Applications: CBD is seeing widespread adoption in the pet care segment as pet owners increasingly seek natural alternatives for anxiety, pain, and inflammation management in companion animals. Strategic partnerships between CBD manufacturers and mainstream pet retailers are broadening product accessibility. This diversification into veterinary applications is unlocking a substantial new demand pool that operates independently of human health regulation, supporting incremental revenue for leading CBD producers.
  
  
• E-Commerce Driving Accessibility and Market Penetration: Online retail platforms have become a critical growth channel for CBD products, enabling brands to bypass traditional retail restrictions and reach consumers in geographies where brick-and-mortar distribution remains limited. The e-commerce penetration rate in Europe is anticipated to reach 55.81% by 2029, creating a significant digital distribution opportunity for CBD manufacturers targeting health-conscious consumers across the region. In the United States, the ease of online CBD purchasing has accelerated market reach, particularly for therapeutic-grade isolates and condition-specific wellness products.
  
  

Growth Factors in the Cannabidiol Market

• Rising Prevalence of Chronic Health Conditions: The growing burden of anxiety, chronic pain, insomnia, and epilepsy across global populations is directly fueling demand for CBD-based therapeutic products. According to the CDC, 51.8% of civilian, noninstitutionalized adults in the United States were diagnosed with at least one of ten selected chronic conditions, creating a large addressable patient base for CBD wellness interventions. In Latin America, anxiety, depression, distress, and insomnia each carry prevalence rates of approximately 35%, according to NIH data, underlining the scale of unmet wellness needs that CBD products are positioned to address.
  
  
• Integration of CBD into Mainstream Healthcare: The inclusion of CBD in formal healthcare frameworks is accelerating acceptance and prescription-based adoption. In April 2026, Charlotte's Web was confirmed as an inaugural launch partner for the Centers for Medicare and Medicaid Innovation CBD pilot program, marking the first time physician-authorized CBD access was integrated into the U.S. Medicare system. Charlotte's Web reported 2025 net revenue of USD 49.9 million, reflecting the company's first year of annual growth since 2021 and signaling improving commercial traction as regulatory acceptance deepens.
  
  
• Strong B2B Demand from Pharmaceutical and Consumer Goods Sectors: B2B transactions account for approximately 55.7% of the market, driven by pharmaceutical companies, wellness supplement manufacturers, and personal care brands procuring high-purity CBD inputs for large-scale product formulation. Long-term supply contracts and volume purchasing arrangements provide revenue stability for upstream CBD producers while ensuring consistent raw material access for downstream manufacturers across food, cosmetics, and therapeutic applications.
  
  
• Supportive Government Schemes and Regulatory Frameworks: Government-led programs are creating clear pathways for CBD commercialization. In the United States, the Farm Bill framework enabled a robust domestic hemp supply chain and distribution infrastructure. In Australia, the Special Access Scheme has facilitated CBD prescriptions for anxiety and insomnia, building physician familiarity and patient loyalty. In Germany, post-decriminalization regulatory clarity has opened new consumer and retail channels for CBD brands targeting the European market.
  
  
• Growth in Stress and Mental Wellness Awareness Across MEA: According to Gallup, 52% of workers in the Middle East reported experiencing stress on a daily basis, representing a significant and largely underserved market for CBD-based stress relief and wellness products. As global attitudes toward cannabis and cannabinoids become more accepting and local regulatory frameworks in South Africa and select Gulf markets evolve incrementally, the MEA region presents a frontier opportunity for CBD manufacturers willing to navigate early-stage regulatory environments with targeted product offerings.
  
  

Leading Companies Operating in the Global Cannabidiol Industry:

• Aurora Cannabis Inc.
• Canopy Growth Corporation
• CV Sciences Inc.
• Elixinol Global Limited
• Endoca BV
• Folium Biosciences
• Green Roads of Florida LLC (The Valens Company Inc.)
• Isodiol International Inc.
• Koi CBD
• Medical Marijuana Inc.
• Medterra CBD
• NuLeaf Naturals LLC
• PharmaHemp d.o.o.
• Tilray Brands Inc.

Cannabidiol Market Report Segmentation:

Breakup By Product:

• CBD Oil
• CBD Isolates
• CBD Concentrates
• Others

CBD isolates account for the largest share due to their high purity level of up to 99% cannabidiol, absence of THC, and versatility across medical, wellness, cosmetic, and edible formulations.

Breakup By Source Type:

• Marijuana
• Hemp

Marijuana leads the market with approximately 58.1% of market share, driven by its elevated cannabinoid concentration, synergistic entourage effect with THC, and strong demand in markets where marijuana is legal for both medical and recreational use.

Breakup By Grade:

• Food Grade
• Therapeutic Grade

Therapeutic grade holds the maximum share with around 62.7%, reflecting robust demand for high-purity CBD in clinical and wellness applications and the growing number of studies supporting CBD's efficacy for anxiety, pain, and epilepsy management.

Breakup By Sales Type:

• B2B
• B2C

B2B dominates with approximately 55.7% of market share, supported by bulk purchasing from pharmaceutical companies, wellness brands, and retailers seeking consistent supply of premium CBD inputs for large-scale production.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position with over 40.4% of market share, driven by progressive cannabis legislation, established hemp supply chains, high consumer awareness, and significant investment in CBD research, product development, and distribution infrastructure.

Recent News and Developments in the Cannabidiol Market

• April 2026: Charlotte's Web, a leading Colorado-based CBD company, was confirmed as an inaugural partner for the Centers for Medicare and Medicaid Innovation CBD pilot program, marking the first instance of physician-authorized CBD being integrated into the U.S. Medicare healthcare system. The company also reported 2025 net revenue of USD 49.9 million, its first year of annual revenue growth since 2021, driven by the launch of Brightside hemp THC gummies and expanded sleep-focused wellness products.
  
  
• July 2026: cbdMD's Oasis brand entered into a partnership with Mexcor to expand distribution into South Carolina, broadening the company's geographic footprint across U.S. states. This followed cbdMD's completion of a self-affirmed Generally Recognized as Safe determination, supporting safe daily consumption of up to 200 mg of cannabidiol and reinforcing the brand's credibility in food-grade and supplement product categories.
  
  
• September 2025: CBD Life Sciences Inc. secured a strategic distribution agreement with Smoking Scholars, a prominent New York dispensary, to carry its CBD Vault product line including CBD pain relief cream, massage oil, and CBD-infused tea. The agreement, finalized following the company's participation at the NECANN New Jersey Conference, positioned CBD Life Sciences to capture a share of the competitive New York cannabis and CBD marketplace.
  
  

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302